NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares (diluted) grows, but more slowly than its trailing trend
Q2 FY2026 weighted avg shares (diluted) of 123.37M shares rose 9.7% year over year, behind the +13.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.9% from the prior quarter. Over 3 fiscal years it compounded at +82.0% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +9.7% toward the trailing-twelve-month pace of +13.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 114.4M USD
- Year-over-year change
- +21.2%
- 4-year CAGR
- +59.3%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 114.4M | +21.2% |
| FY2024 | 2024-12-31 | 94.36M | +14.8% |
| FY2023 | 2023-12-31 | 82.16M | +333.2% |
| FY2022 | 2022-12-31 | 18.97M | +6.8% |
| FY2021 | 2021-12-31 | 17.75M | — |
Weighted Avg Shares (Diluted) vs competitors
How NAMS compares with its peers on the latest reported figures
- NAMS's LTM Jun 2026 weighted avg shares (diluted) of 119.47M shares is the 2nd highest of the 9 companies compared; the peer median is 53.24M shares.
- Its year-over-year change of +13.7% is the 4th highest of 9, against a peer median of +8.1%.
- Over three fiscal years its annual growth of +82.0% compares with a peer median of +12.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | 180.46M | +5.8% | +11.8% | |
| LTM Jun 2026 | 119.47M | +13.7% | +82.0% | |
| LTM Jun 2026 | 114.45M | +2.5% | +13.6% | |
| LTM Sep 2026 | 108.82M | +29.3% | +12.4% | |
| LTM Mar 2026 | 61.23M | +1.8% | +14.3% | |
SEPNSepterna, Inc. | LTM Sep 2026 | 45.24M | +9.0% | — |
BIOABioAge Labs, Inc. | LTM Mar 2026 | 37.57M | +7.3% | +1.7% |
| LTM Jun 2026 | 25.77M | +17.2% | +9.4% | |
| FY2025 | 10.66M | +75.3% | +38.5% | |
| Peer median (excluding NAMS) | 53.24M | +8.1% | +12.4% | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 102.69M | 14.09M | 45.56M | 22.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 59K |
| Gross Profit | 0 | 102.69M | 14.09M | 45.56M | 22.44M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 99.7% |
| Research & Development | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M |
| Selling, General & Admin | 5.68M | 19.51M | 37.63M | 70.45M | 106.3M |
| Operating Expenses | 34.98M | 106.25M | 197.06M | 221.85M | 248.13M |
| Depreciation & Amortization | 5K | 9K | 49K | 113K | 220K |
| EBITDA | (41.37M) | (22.34M) | (176.86M) | (241.49M) | (242.33M) |
| EBITDA Margin | — | -21.8% | -1255.2% | -530.0% | -1076.9% |
| Operating Income | (34.98M) | (3.56M) | (182.97M) | (176.29M) | (225.68M) |
| Operating Margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Interest Income | 0 | 0 | 10.22M | 16.88M | 27.59M |
| Interest Expense | 411K | 287K | 6.8M | 0 | 0 |
| Other Income / Expenses | (6.81M) | (19.08M) | 6.06M | (65.31M) | 21.86M |
| Income Before Tax | (41.79M) | (22.63M) | (176.91M) | (241.6M) | (203.82M) |
| Pre-Tax Margin | — | -22.0% | -1255.6% | -530.3% | -905.7% |
| Income Tax Expense | 0 | 0 | 27K | (1K) | 0 |
| Net Income | (41.79M) | (22.63M) | (176.94M) | (241.6M) | (203.82M) |
| Net Margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
| EPS (Basic) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| EPS (Diluted) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| Weighted Avg Shares | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
| Weighted Avg Shares (Diluted) | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.